Inventor · disambiguated record
David Hickman
Also filed as: HICKMAN DAVID · HICKMAN DAVID T
13 granted patents·10 pending applications·109 citations·filing 2004–2025
91Inventor score
Files withAC IMMUNE SA6JANSSEN PHARMACEUTICALS INC5AVANTI POLAR LIPIDS INC4TOSI PIERRE-FRANCOIS4NICOLAU YVES CLAUDE2
Top patents by PatentIndex Score
23 records- 0196US7772375B2Monoclonal antibodies that recognize epitopes of amyloid-betaAC IMMUNE SA·Filed 2006·Granted Aug 10, 2010·51 cites·15 claims
- 0289US9241988B2Disaccharide synthetic lipid compounds and uses thereofAVANTI POLAR LIPIDS INC·Filed 2013·Granted Jan 26, 2016·19 cites·12 claims
- 0388US11591377B2Heterologous administration of tau vaccinesJANSSEN PHARMACEUTICALS INC·Filed 2020·Granted Feb 28, 2023·2 cites·20 claims
- 0478US9687447B2Method for preparing liposome-based constructsREIS PEDRO·Filed 2011·Granted Jun 27, 2017·8 cites·3 claims
- 0578US9518078B2Disaccharide synthetic lipid compounds and uses thereofAVANTI POLAR LIPIDS INC·Filed 2013·Granted Dec 13, 2016·5 cites·13 claims
- 0678US8926983B2Method for improving memory in AD patientsNICOLAU YVES CLAUDE·Filed 2005·Granted Jan 6, 2015·3 cites·8 claims
- 0777US9975946B2Antibodies obtainable using supramolecular constructsAC IMMUNE SA·Filed 2014·Granted May 22, 2018·2 cites·13 claims
- 0876US8663650B2Methods and compositions comprising supramolecular constructsNICOLAU YVES CLAUDE·Filed 2004·Granted Mar 4, 2014·8 cites·8 claims
- 0974US10143744B2Disaccharide synthetic lipid compounds and uses thereofAVANTI POLAR LIPIDS INC·Filed 2016·Granted Dec 4, 2018·2 cites·20 claims
- 1074US2025326806A1Compositions of Phosphorylated Tau Peptides and Uses ThereofJANSSEN PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1172US9289488B2Vaccine engineeringHICKMAN DAVID·Filed 2011·Granted Mar 22, 2016·3 cites·18 claims
- 1271US8409580B2Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancersTOSI PIERRE-FRANCOIS·Filed 2010·Granted Apr 2, 2013·2 cites·19 claims
- 1370US11958889B2Compositions of phosphorylated tau peptides and uses thereofJANSSEN PHARMACEUTICALS INC·Filed 2018·Granted Apr 16, 2024·0 cites·24 claims
- 1469US2023257433A1Heterologous Administration of Tau VaccinesJANSSEN PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1568US2010297132A1Monoclonal antibodyAC IMMUNE SA·Filed 2009·Application pending·0 cites
- 1666US7807171B2Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancersAC IMMUNE SA·Filed 2004·Granted Oct 5, 2010·4 cites·21 claims
- 1765US2021388044A1Compositions of Phosphorylated Tau Peptides and Uses ThereofJANSSEN PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1852US2011070613A1Monoclonal AntibodyAC IMMUNE SA·Filed 2010·Application pending·0 cites
- 1942US2006233758A1Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancersTOSI PIERRE-FRANCOIS·Filed 2005·Application pending·0 cites
- 2041US2005244419A1Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancersTOSI PIERRE-FRANCOIS·Filed 2005·Application pending·0 cites
- 2141US2008026995A1Therapeutic vaccine targeted against p-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancersAC IMMUNE SA·Filed 2006·Application pending·0 cites
- 2240US2005255561A1Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancersTOSI PIERRE-FRANCOIS·Filed 2005·Application pending·0 cites
- 2335US2017349618A1Disaccharide synthetic lipid compounds and uses thereofAVANTI POLAR LIPIDS INC·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →